Research programme: cancer therapeutics - Artios Pharma/Merck KGaA
Alternative Names: DNA damage response targets - Artios Pharma/Merck KGaA; Precision oncology drugs - Artios Pharma/Merck KGaALatest Information Update: 07 Dec 2020
At a glance
- Originator Artios Pharma; Merck KGaA
- Class Antineoplastics
- Mechanism of Action DNA repair enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer